Long COVID Symptoms Persist Through 12 Months
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Aug. 15, 2023 -- Long COVID symptoms can persist for up to 12 months, according to research published in the Aug. 11 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Juan Carlos C. Montoy, M.D., Ph.D., from the University of California in San Francisco, and colleagues analyzed data on self-reported symptoms from 1,296 adults with COVID-like illness who were tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The researchers observed a substantial decrease in the prevalence of any symptoms between baseline and three-month follow-up, from 98.4 to 48.2 percent and from 88.2 to 36.6 percent, respectively, for those who received a positive and a negative SARS-CoV-2 test result. Through 12 months, there was a decrease in persistent symptoms; at 12 months, there was no difference seen between the groups. Symptoms that emerged or reemerged at six, nine, and 12 months were reported in both groups.
Nicole D. Ford, Ph.D., from the CDC in Atlanta, and colleagues estimated the prevalence of long COVID using data from surveys completed between June 1 to 13, 2022, and June 7 to 19, 2023. The researchers found that the prevalence of long COVID decreased from 7.5 to 6.0 percent among the overall U.S. adult population and from 18.9 to 11.0 percent among U.S. adults reporting previous COVID-19. Prevalence decreased from June 1 to 13, 2022, through Jan. 4 to 16, 2023, among both groups, before stabilizing. Overall, 26.4 percent of adults with long COVID reported significant activity limitation during June 7 to 19, 2023; the prevalence did not change over time.
"These findings highlight the importance of COVID prevention, including staying up to date with recommended COVID-19 vaccination," Ford and colleagues write.
Several authors from the Montoy study disclosed ties to the diagnostics and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Further Support and Information on COVID-19
Read this next
Residual Risk Seen for Death, Postacute Sequelae in Third Year After COVID-19 Hospitalization
THURSDAY, June 13, 2024 -- For individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the risks for death and postacute sequelae of COVID-19...
Systemic Side Effects of COVID-19 Vaccine Tied to Greater nAB Response
TUESDAY, June 11, 2024 -- Short-term systemic side effects of the severe acute respiratory coronavirus 2 (SARS-CoV-2) mRNA vaccine are associated with greater long-lasting...
Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.